CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Sage Therapeutics, Inc. - SAGE CFD

11.63
0.68%
Market Trading Hours* (UTC) Open now
Closes on Monday at 20:00

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.10
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.026262 %
Charges from full value of position ($-4.99)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026262%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.00404 %
Charges from full value of position ($0.77)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.00404%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 11.71
Open 11.6
1-Year Change -75.09%
Day's Range 11.6 - 11.86
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jul 12, 2024 11.71 0.03 0.26% 11.68 11.90 11.46
Jul 11, 2024 11.68 0.44 3.91% 11.24 12.01 11.16
Jul 10, 2024 10.98 -0.40 -3.51% 11.38 11.50 10.79
Jul 9, 2024 11.42 0.61 5.64% 10.81 11.58 10.71
Jul 8, 2024 10.90 0.05 0.46% 10.85 11.07 10.35
Jul 5, 2024 10.72 0.24 2.29% 10.48 10.93 10.30
Jul 3, 2024 10.53 -0.29 -2.68% 10.82 10.92 10.53
Jul 2, 2024 10.77 0.08 0.75% 10.69 10.96 10.55
Jul 1, 2024 10.99 0.24 2.23% 10.75 11.20 10.58
Jun 28, 2024 10.77 0.20 1.89% 10.57 10.84 10.49
Jun 27, 2024 10.65 -0.13 -1.21% 10.78 10.83 10.51
Jun 26, 2024 10.81 0.08 0.75% 10.73 11.08 10.58
Jun 25, 2024 10.83 -0.52 -4.58% 11.35 11.36 10.80
Jun 24, 2024 11.47 0.51 4.65% 10.96 11.72 10.96
Jun 21, 2024 11.05 0.32 2.98% 10.73 11.27 10.44
Jun 20, 2024 10.62 0.18 1.72% 10.44 10.76 10.18
Jun 18, 2024 10.70 -0.62 -5.48% 11.32 11.35 10.67
Jun 17, 2024 11.23 -0.36 -3.11% 11.59 11.98 11.12
Jun 14, 2024 11.95 0.59 5.19% 11.36 12.10 11.36
Jun 13, 2024 11.45 0.67 6.22% 10.78 11.60 10.74

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Sage Therapeutic Company profile

About SAGE Therapeutics Inc

SAGE Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing medicines with debilitating disorders of the brain. The Company's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD), in adults. The Company's products also include ZULRESSO (Brexanolone) CIV Injection, Zuranolone (SAGE-217), SAGE-324 and SAGE-718. Its next advanced product candidate is SAGE-217, is an oral compound that is in Phase III clinical development in PPD and depressive disorder (MDD). Zuranolone is a neuroactive steroid that, like brexanolone, is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. SAGE-324 is a GABAA receptor positive allosteric modulator intended for chronic oral dosing and conducting a placebo-controlled Phase II clinical trial evaluating the safety and efficacy of SAGE-324 in the treatment of essential tremor.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, SAGE Therapeutics Inc revenues decreased 99% to $6.3M. Net loss totaled $457.9M vs. income of $606.1M. Revenues reflect Collaboration revenue decrease from $1.11B to $0K, Product decrease of 6% to $6.3M. Net loss reflects Stock-based Compensation in R&D increase of 17% to $49.7M (expense), Stock-based Compensation in SGA increase of 6% to $54.9M (expense), Other income (expense).

Equity composition

Common Stock, $0.0001 Par, 07/14, auth. 120M shares,. 24,961,926 issd,. Insiders owns approx. 20.03%.

Industry: Bio Therapeutic Drugs

215 1st St
CAMBRIDGE
MASSACHUSETTS 02142
US

People also watch

Gold

2,421.69 Price
+0.470% 1D Chg, %
Long position overnight fee -0.0191%
Short position overnight fee 0.0109%
Overnight fee time 21:00 (UTC)
Spread 0.30

US100

20,507.00 Price
+0.820% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

ETH/USD

3,365.72 Price
+5.050% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

BTC/USD

63,041.10 Price
+4.730% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 630,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading